Your session is about to expire
← Back to Search
Radiation
Hypofractionated Radiotherapy for Endometrial and Cervical Cancers (HERA Trial)
N/A
Recruiting
Led By Puja S. Venkat, MD
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Histologically confirmed endometrial or cervical cancer
Surgical resection of the primary tumor
Must not have
Must not meet indications for receiving concurrent chemotherapy as standard of care
History of prior irradiation to the area to be treated
Timeline
Screening 3 weeks
Treatment Varies
Follow Up treatment to 12 weeks after completion of radiotherapy
Awards & highlights
No Placebo-Only Group
Summary
"This trial is testing a new type of radiation therapy called hypo-fractionated radiation therapy for women who have undergone surgery to remove endometrial and/or cervical tumors. The study aims to see if this
Who is the study for?
This trial is for women who have had surgery to remove endometrial or cervical cancer. They should be candidates for post-surgery radiation therapy and able to undergo MRI or CT scans. Specific details about inclusion and exclusion criteria are not provided, but typically participants must meet certain health standards.
What is being tested?
The study tests hypo-fractionated external beam radiotherapy after surgery in women with endometrial or cervical cancers. This approach uses fewer, larger doses of radiation compared to the standard method, aiming to maintain effectiveness while reducing treatment time.
What are the potential side effects?
While specific side effects are not listed, hypo-fractionated radiotherapy may include skin irritation, fatigue, mild swelling at the treatment site, and potential impacts on nearby organs such as the bladder or bowel.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My cancer diagnosis is confirmed for either endometrial or cervical cancer.
Select...
I have had surgery to remove my primary tumor.
Select...
My cancer is in the early to advanced stages but hasn't spread far.
Select...
I am 18 years old or older.
Select...
I can care for myself but may not be able to do active work.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not required to have chemotherapy as part of my standard treatment.
Select...
I have had radiation therapy to the area that needs treatment now.
Select...
I am currently being treated for another cancer.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 weeks after completion of radiotherapy until 5 years after completion of radiotherapy
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after completion of radiotherapy until 5 years after completion of radiotherapy
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Evaluate acute radiation toxicity
Secondary study objectives
Evaluate distant metastasis
Evaluate late toxicity
Evaluate local control
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hypofractionated External beam RadiotherapyExperimental Treatment1 Intervention
5 daily treatment sessions of MRI or CT-Guided Stereotactic Body Radiation Therapy (SBRT).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
External beam Radiotherapy
2014
N/A
~100
Find a Location
Who is running the clinical trial?
Jonsson Comprehensive Cancer CenterLead Sponsor
370 Previous Clinical Trials
35,134 Total Patients Enrolled
Puja S. Venkat, MDPrincipal InvestigatorUniversity of California at Los Angeles
Share this study with friends
Copy Link
Messenger